drugset / Trial / NCT07447817
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Phase 2
Not yet recruiting
26 enrolled
John Mascarenhas
Karyopharm Therapeutics Inc · collabNational Cancer Institute (NCI) · collabSobi, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Timeline
- Start
- 2026-05-04
- Primary completion
- 2030-05-24
- Completion
- 2030-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | 200 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |